DiviTum®TKa aims to guide clinicians to make more informed decisions about medical treatment and follow-up, thereby delivering the right treatment to the right patient at the right time
Breast cancer is the most common form of cancer among women today, affecting approximately 362,000 individuals in the EU and 233,000 in the US each year. Better tests for evaluating therapeutic efficacy, such as Biovica’s DiviTum®TKa biomarker assay, aim to improve care for metastatic breast cancer.
Clinical trials and Collaborations
Biovica has successfully worked to realize its vision for Divitum®TKa by initiating collaborations with globally-renowned research institutes such as the Karolinska Institute and the Dana Farber Cancer institute, as well as the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).
Click on the logos below and read more about our Collaborations
Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Biovica is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.